Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (3): 307-311.

Previous Articles Next Articles

Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population

HUANG Qiong¹, ZHANG Liu-fu², CHENG Yan³, SI Li⁴, WEI Wei¹

¹Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, Anhui, China
²Department of Neurology, the Third Affiliated Hospital of Anhui Medical University, First People's Hospital in Hefei, Hefei 230061, Anhui, China
³Department of Pediatrics
⁴Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China

Received:2012-08-20 Revised:2012-12-03 Online:2013-03-26 Published:2013-04-02
Contact: WEI Wei, correspondence author, male, Ph.D, tutor of Ph.D. student, engaged in antiinflammatory - immunity pharmacology.Tel: 0551-5161209 E-mail: wwei@ahmu.edu.cn
Supported by:
This study was supported by the National Natural Science Foundation of China Grants(81202596), Specialized Research Fund for the Doctoral Program of Higher Education (20113420120006), Grants for Scientific Research of BSKY (XJ201021) from Anhui Medical University, Research Foundation of Anhui Medical University (2011xkj011), Anhui province Nature Science Foundation in University (KJ2012Z158)

Abstract

Abstract: AIM: To investigate the association of β3-adrenergic receptor gene Trp64Arg polymorphism with hyperuricemia in a Chinese male type 2 diabetes mellitus patients population.METHODS: 196 hyperuricemic and 196 normouricemic male subjects were genotyped in this study. Body mass index (BMI), waist to hip ratio (WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), serum uric acid, urea nitrogen, creatinine, triglyceride, total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), fasting plasma glucose (FPG), postprandial plasma glucose (PPG) were detected.RESULTS: We found patients with different Trp64Arg genotype showed significant differences in average uric acid concentrations (599.53±113.70 vs 529.78±81.10 vs 507.33±74.27, P<0.01) among CC, CT and TT genotype and there were significantly higher average uric acid concentrations in Trp64Arg TC+CC genotype individuals (557.95±99.91 vs 503.47±69.40 μmol/L, P<0.01) than those TT genotype subjects in the hyperuricemic group.CONCLUSION: Trp64Arg polymorphism was associated with hyperuricemia in a Chinese male population with type 2 diabetes mellitus.

Key words: Beta-3-adrenergic receptor, Genetic polymorphism, Hyperuricemia, Uric acid, Type 2 diabetes mellitus, Aassociation analysis

CLC Number:

R968

HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei. Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.

References

[1] Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout[J]. Am J Manag Care, 2005, 11(15 Suppl): S459-464; quiz S65-68.
[2] Dalbeth N, Haskard DO. Mechanisms of inflammation in gout[J]. Rheumatology (Oxford), 2005, 44(9): 1090-1096.
[3] Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout[J]. Arthritis Res Ther, 2006, 8(Suppl 1): S2.
[4] Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome[J]. Cleve Clin J Med, 2006, 73(12): 1059-1064.
[5] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes[J]. Diabetes Care, 2009, 32(9): 1737-1742.
[6] Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers[J]. Eur J Epidemiol, 2003, 18(6): 523-530.
[7] Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study[J]. J Korean Med Sci, 2005, 20(6): 1029-1033.
[8] Rho YH, Choi SJ, Lee YH, et al. The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor[J]. Rheumatol Int, 2007, 27(9): 835-839.
[9] Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study[J]. Lancet, 2008, 372(9654): 1953-1961.
[10] Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study[J]. Metabolism, 2005, 54(11): 1435-1441.
[11] Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country[J]. BMC Public Health, 2004, 4: 9.
[12] Perfetti R, Hui H, Chamie K, et al. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity[J]. J Mol Endocrinol, 2001, 27(2): 133-144.
[13] Chamberlain PD, Jennings KH, Paul F, et al. The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle[J]. Int J Obes Relat Metab Disord, 1999, 23(10): 1057-1065.
[14] Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene[J]. N Engl J Med,1995, 333(6): 343-347.
[15] Widen E, Lehto M, Kanninen T, et al. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns[J]. N Engl J Med, 1995, 333(6): 348-351.
[16] Clement K, Vaisse C, Manning BS, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity[J]. N Engl J Med, 1995, 333(6): 352-354.
[17] Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96)[J]. J Rheumatol, 2001, 28(7): 1640-1646.
[18] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge[J]. Clin Chem, 1972, 18(6): 499-502.
[19] Doherty M. New insights into the epidemiology of gout[J]. Rheumatology (Oxford), 2009, 48 (Suppl 2): ii2-ii8.
[20] Roddy E, Zhang W, Doherty M. The changing epidemiology of gout[J]. Nat Clin Pract Rheumatol, 2007, 3(8): 443-449.
[21] Chuang SY, Lee SC, Hsieh YT, et al. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008[J]. Asia Pac J Clin Nutr, 2011, 20(2): 301-308.
[22] Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome[J]. J Chin Med Assoc, 2006, 69(11): 512-516.
[23] Coe FL, Evan A, Worcester E. Kidney stone disease[J]. J Clin Invest, 2005, 115(10): 2598-2608.
[24] Bea JW, Lohman TG, Cussler EC, et al. Lifestyle modifies the relationship between body composition and adrenergic receptor genetic polymorphisms, ADRB2, ADRB3 and ADRA2B: a secondary analysis of a randomized controlled trial of physical activity among postmenopausal women[J]. Behav Genet, 2010, 40(5): 649-659.

Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[3]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[4]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[5]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[6]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[7]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[8]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[9]	CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
[10]	WU Dan, DIAO Yong, XU Xianxiang. Progress in research on hyperuricemia cell model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 236-240.
[11]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[12]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[13]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[14]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[15]	SUN Shanshan, QU Lianyue, DU Rongrong, LIN Jianyang. Research progress on drug therapy of hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 589-594.